MA29378B1 - Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer - Google Patents
Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancerInfo
- Publication number
- MA29378B1 MA29378B1 MA30267A MA30267A MA29378B1 MA 29378 B1 MA29378 B1 MA 29378B1 MA 30267 A MA30267 A MA 30267A MA 30267 A MA30267 A MA 30267A MA 29378 B1 MA29378 B1 MA 29378B1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- treatment
- pharmaceutical composition
- diphenyluree
- carboxyaryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE QUI COMPREND LE COMPOSÉ DE LA FORMULE (I) À UNE CONCENTRATION ÉLEVÉE ET AU MOINS UN EXCIPIENT PHARMACEUTIQUEMENT ACCEPTABLE, L'UTILISATION DE LA COMPOSITION POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES, TELLES QUE LE CANCER, SOIT COMME SEUL AGENT OU EN COMBINAISON AVEC D¿AUTRES THÉRAPIES ANTICANCÉREUSES, AINSI QUE LE PROCÉDÉ DE PRÉPARATION DE LADITE COMPOSITION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65882705P | 2005-03-07 | 2005-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29378B1 true MA29378B1 (fr) | 2008-04-01 |
Family
ID=36507604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30267A MA29378B1 (fr) | 2005-03-07 | 2007-10-02 | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer |
Country Status (38)
Country | Link |
---|---|
US (2) | US9737488B2 (fr) |
EP (1) | EP1868579B1 (fr) |
JP (1) | JP5304241B2 (fr) |
KR (1) | KR101335932B1 (fr) |
CN (2) | CN104688697A (fr) |
AR (1) | AR054234A1 (fr) |
AT (1) | ATE482693T1 (fr) |
AU (1) | AU2006222365B2 (fr) |
BR (1) | BRPI0608840B8 (fr) |
CA (1) | CA2601955C (fr) |
CR (1) | CR9348A (fr) |
CU (1) | CU23821A3 (fr) |
CY (1) | CY1111065T1 (fr) |
DE (1) | DE602006017188D1 (fr) |
DK (1) | DK1868579T3 (fr) |
DO (1) | DOP2006000057A (fr) |
ES (1) | ES2351612T3 (fr) |
GT (1) | GT200600096A (fr) |
HK (2) | HK1118019A1 (fr) |
HN (1) | HN2006009702A (fr) |
HR (1) | HRP20100674T1 (fr) |
IL (1) | IL185517A (fr) |
MA (1) | MA29378B1 (fr) |
MX (1) | MX2007010856A (fr) |
MY (1) | MY162319A (fr) |
NO (1) | NO343834B1 (fr) |
NZ (1) | NZ561178A (fr) |
PE (1) | PE20061345A1 (fr) |
PL (1) | PL1868579T3 (fr) |
PT (1) | PT1868579E (fr) |
SG (1) | SG160364A1 (fr) |
SI (1) | SI1868579T1 (fr) |
TN (1) | TNSN07341A1 (fr) |
TW (1) | TWI324928B (fr) |
UA (1) | UA93673C2 (fr) |
UY (1) | UY29410A1 (fr) |
WO (1) | WO2006094626A1 (fr) |
ZA (1) | ZA200707638B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
JP4860474B2 (ja) | 2003-05-20 | 2012-01-25 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
UA91520C2 (en) | 2004-09-29 | 2010-08-10 | Баер Шеринг Фарма Акциенгезельшафт | Thermodynamically stable form of tosylate |
UA93673C2 (ru) | 2005-03-07 | 2011-03-10 | Баер Шеринг Фарма Акциенгезельшафт | Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka |
US20090068146A1 (en) | 2005-10-31 | 2009-03-12 | Scott Wilhelm | Diaryl ureas and combinations |
TW200820991A (en) * | 2006-07-10 | 2008-05-16 | Elan Pharma Int Ltd | Nanoparticulate sorafenib formulations |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
CA2675980C (fr) | 2007-01-19 | 2016-06-21 | Bayer Healthcare Llc | Utilisation de dast dans le traitement des cancers a resistance acquise a des inhibiteurs de kit |
WO2009106825A1 (fr) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphes de sorafénib et leurs sels |
ES2969144T3 (es) | 2008-05-15 | 2024-05-16 | Celgene Corp | Formulaciones orales de análogos de citidina y métodos de uso de los mismos |
WO2010142678A2 (fr) * | 2009-06-12 | 2010-12-16 | Ratiopharm Gmbh | Polymorphes de 4-[4-[[4-chloro-3-(trifluorométhyl)phényl]carbamoylamino]phénoxy]-n-méthyl-pyridine-2-carboxamide |
WO2011092663A2 (fr) | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | Solvate de diméthylsulfoxyde du 4-(4-{3-[4-chloro-3-(trifluorométhyl)phényl]uréido}phénoxy)-n2-méthylpyridine-2-carboxamide |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
WO2012041987A1 (fr) | 2010-10-01 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué |
EP2559431A1 (fr) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide |
EP2806860B1 (fr) | 2012-01-23 | 2023-04-19 | Sandoz AG | Composition pharmaceutique contenant du tosylate sorafenib cristallin |
CA2875986C (fr) | 2012-06-04 | 2020-06-09 | Pharmacyclics, Inc. | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
MD3265084T2 (ro) | 2015-03-03 | 2024-05-31 | Pharmacyclics Llc | Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton |
US10597820B2 (en) * | 2015-05-14 | 2020-03-24 | DuPont Nutrition USA, Inc. | Method of making bleached microcrystalline cellulose |
CA3016809C (fr) * | 2016-03-14 | 2024-03-12 | Santen Pharmaceutical Co., Ltd. | Agent antiseptique contenant de la meglumine ou un sel correspondant |
CN106344530B (zh) * | 2016-09-30 | 2019-03-19 | 京津冀联创药物研究(北京)有限公司 | 一种索拉非尼组合物及其制备方法 |
US11712418B2 (en) | 2017-05-26 | 2023-08-01 | Bruin Biosciences, Inc. | Chemoembolization agents |
US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
WO2018211336A2 (fr) | 2018-09-07 | 2018-11-22 | Alvogen Malta Operations (Row) Ltd | Forme galénique solide contenant du tosylate de sorafénib |
CA3118324A1 (fr) | 2018-11-01 | 2020-05-07 | Syros Pharmaceuticals, Inc. | Methodes de traitement du cancer chez des patients identifies par biomarqueurs avec des inhibiteurs non covalents de la kinase cycline-dependante 7 (cdk7) |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3125359A (en) * | 1964-03-17 | Push-pull breakaway coupling | ||
NL282262A (fr) * | 1961-11-08 | |||
AU594098B2 (en) | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
DK607188A (da) | 1987-11-02 | 1989-06-22 | Merck & Co Inc | Tablet indeholdende en phthalazineddikesyreforbindelse |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
US6106865A (en) * | 1995-01-09 | 2000-08-22 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
WO1997004765A1 (fr) | 1995-07-25 | 1997-02-13 | Smithkline Beecham Corporation | INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE |
AU723730B2 (en) | 1996-04-23 | 2000-09-07 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of IMPDH enzyme |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
DE69826695T2 (de) | 1997-05-23 | 2006-02-02 | Bayer Pharmaceuticals Corp., West Haven | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen |
JP2002500650A (ja) | 1997-05-23 | 2002-01-08 | バイエル、コーポレイション | Rafキナーゼ阻害剤 |
EP1041982B1 (fr) | 1997-12-22 | 2011-10-19 | Bayer HealthCare LLC | Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques substituees |
ES2153809T3 (es) | 1997-12-22 | 2005-07-16 | Bayer Pharmaceuticals Corporation | Inhibicion de la cinasa raf por uso de difnil-ureas sustituidas simetrica y asimetricamente. |
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
ES2155817T3 (es) | 1997-12-22 | 2007-06-16 | Bayer Pharmaceuticals Corp. | Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
PL341356A1 (en) | 1997-12-22 | 2001-04-09 | Bayer Ag | Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas |
ATE300299T1 (de) | 1997-12-22 | 2005-08-15 | Bayer Pharmaceuticals Corp | Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen |
JP3887769B2 (ja) | 1997-12-22 | 2007-02-28 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるp38キナーゼの阻害 |
US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
US20030087849A1 (en) | 2001-07-03 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of HKR1 expression |
US6117451A (en) | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
EP1140840B1 (fr) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf |
US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
ME00275B (fr) * | 1999-01-13 | 2011-02-10 | Bayer Corp | DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
KR100787254B1 (ko) * | 1999-01-22 | 2007-12-20 | 기린 홀딩스 가부시키가이샤 | 퀴놀린유도체 및 퀴나졸린유도체 |
US20020071857A1 (en) * | 2000-08-18 | 2002-06-13 | Kararli Tugrul T. | Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE353889T1 (de) | 2001-03-23 | 2007-03-15 | Bayer Pharmaceuticals Corp | Rho-kinase inhibitoren |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
WO2002085857A2 (fr) | 2001-04-20 | 2002-10-31 | Bayer Corporation | Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl |
US20030207914A1 (en) * | 2001-04-20 | 2003-11-06 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
SI1450799T1 (sl) * | 2001-12-03 | 2007-02-28 | Bayer Pharmaceuticals Corp | Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov |
CA2466762A1 (fr) | 2001-12-04 | 2003-06-12 | Onyx Pharmaceuticals, Inc. | Inhibiteurs de la voie raf-mek-erk pour traiter le cancer |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
WO2003068223A1 (fr) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Urees aryliques a kinase de raf et activite inhibitrice d'angiogenese |
AU2003209116A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
WO2003101444A1 (fr) * | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Composes et derives de diaryluree utilises comme inhibiteurs de chk-1 dans le traitement du cancer |
CA2516624C (fr) | 2003-02-28 | 2013-05-14 | Bayer Pharmaceuticals Corporation | Derives de 2-oxo-1,3,5-perhydrotriazapine destines au traitement de maladies hyperproliferatives, angiogeniques et inflammatoires |
CA2516931C (fr) | 2003-02-28 | 2014-09-09 | Bayer Pharmaceuticals Corporation | Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles |
CA2516627A1 (fr) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Derives de pyridine substitues utilises pour traiter des cancers et d'autres troubles |
US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US6896863B2 (en) * | 2003-04-01 | 2005-05-24 | E. I. Du Pont De Nemours And Company | Sodium cyanide process |
JP4860474B2 (ja) | 2003-05-20 | 2012-01-25 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
US20060234931A1 (en) | 2003-07-17 | 2006-10-19 | Biggs William H Iii | Treatment of diseases with kinase inhibitors |
DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
WO2005027972A2 (fr) * | 2003-09-23 | 2005-03-31 | Novartis Ag | Polytherapie combinant un inhibiteur des recepteurs du facteur vegf avec un agent chimiotherapeutique |
US7552093B2 (en) * | 2003-12-04 | 2009-06-23 | Black Duck Software, Inc. | Resolving license dependencies for aggregations of legally-protectable content |
WO2005059179A1 (fr) | 2003-12-12 | 2005-06-30 | Bayer Pharmaceutical Corporation | Procede de prediction et de pronostic du cancer, et surveillance de traitement anticancereux |
WO2005110994A2 (fr) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Derives de pyrazolyl uree substitues utiles dans le traitement du cancer |
JP2008503560A (ja) | 2004-06-22 | 2008-02-07 | ファイザー・プロダクツ・インク | ジアザビシクロ系のヒスタミン−3受容体アンタゴニスト |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
EP1796642B1 (fr) | 2004-08-27 | 2008-05-21 | Bayer Pharmaceuticals Corporation | Compositions pharmaceutiques sous forme de dispersions solides pour le traitement du cancer |
UA91520C2 (en) | 2004-09-29 | 2010-08-10 | Баер Шеринг Фарма Акциенгезельшафт | Thermodynamically stable form of tosylate |
BRPI0515944B1 (pt) | 2004-09-29 | 2021-11-09 | Bayer Healthcare Llc | Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida |
UA93673C2 (ru) | 2005-03-07 | 2011-03-10 | Баер Шеринг Фарма Акциенгезельшафт | Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka |
US20090306020A1 (en) * | 2005-05-27 | 2009-12-10 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
CA2609389A1 (fr) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Traitement de combinaison comprenant un compose diaryluree et des inhibiteurs de pi3- ou akt-kinase ou de mtor (rapamycines) pour le traitement du cancer |
WO2007015947A2 (fr) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Methodes et trousses pour la prediction du succes therapeutique, de la survie sans recidive et globale dans des therapies du cancer |
AU2006304764A1 (en) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
WO2007053573A2 (fr) | 2005-10-31 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Traitement du cancer au moyen de sorafenib |
US20090068146A1 (en) * | 2005-10-31 | 2009-03-12 | Scott Wilhelm | Diaryl ureas and combinations |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
AU2006312059A1 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
JP2009515166A (ja) | 2005-11-02 | 2009-04-09 | バイエル ヘルスケア エルエルシー | がんの予測及び予後の検査方法、並びにがん治療のモニタリング |
JP5075832B2 (ja) | 2005-11-10 | 2012-11-21 | バイエル・ファルマ・アクチェンゲゼルシャフト | 肺高血圧を処置するためのジアリールウレア |
WO2007059155A1 (fr) | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Traitement de cancers a resistance a des agents chimiotherapeutiques |
EP1957069A2 (fr) | 2005-11-14 | 2008-08-20 | Bayer Healthcare, LLC | Traitement de cancers a resistance acquise a des inhibiteurs de kit |
CN101454668A (zh) | 2005-11-14 | 2009-06-10 | 拜耳医药保健有限责任公司 | 癌症预测与预后以及监测癌症治疗的方法 |
WO2007064872A2 (fr) | 2005-12-01 | 2007-06-07 | Bayer Healthcare Llc | Composes de l'uree utilises dans le traitement du cancer |
US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
DE602007012589D1 (de) | 2006-12-20 | 2011-03-31 | Bayer Healthcare Llc | 4-ä4-Ä(ä3-TERT-BUTYL-1-Ä3-(HYDROXYMETHYL)-PHENYLÜ-1H-PYRAZOL-5-YLü-CARBAMOYL)-AMINOÜ-3-FLUOROPHENOXYü -N-METHYLPYRIDIN-2-CARBOXAMID SOWIE PRODRUGS UND |
CA2675980C (fr) | 2007-01-19 | 2016-06-21 | Bayer Healthcare Llc | Utilisation de dast dans le traitement des cancers a resistance acquise a des inhibiteurs de kit |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2014518232A (ja) | 2011-06-28 | 2014-07-28 | バイエル・ヘルスケア・エルエルシー | ソラフェニブを含有する眼科用局所医薬組成物 |
EP2559431A1 (fr) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide |
-
2006
- 2006-02-22 UA UAA200711110A patent/UA93673C2/ru unknown
- 2006-02-22 EP EP06707141A patent/EP1868579B1/fr not_active Revoked
- 2006-02-22 ES ES06707141T patent/ES2351612T3/es active Active
- 2006-02-22 WO PCT/EP2006/001574 patent/WO2006094626A1/fr active Application Filing
- 2006-02-22 BR BRPI0608840A patent/BRPI0608840B8/pt active IP Right Grant
- 2006-02-22 JP JP2008500066A patent/JP5304241B2/ja active Active
- 2006-02-22 SI SI200630863T patent/SI1868579T1/sl unknown
- 2006-02-22 AU AU2006222365A patent/AU2006222365B2/en active Active
- 2006-02-22 PL PL06707141T patent/PL1868579T3/pl unknown
- 2006-02-22 CN CN201510055041.5A patent/CN104688697A/zh active Pending
- 2006-02-22 CA CA2601955A patent/CA2601955C/fr active Active
- 2006-02-22 PT PT06707141T patent/PT1868579E/pt unknown
- 2006-02-22 US US11/885,930 patent/US9737488B2/en active Active
- 2006-02-22 NZ NZ561178A patent/NZ561178A/en unknown
- 2006-02-22 DK DK06707141.5T patent/DK1868579T3/da active
- 2006-02-22 SG SG201001549-3A patent/SG160364A1/en unknown
- 2006-02-22 CN CN200680007187.1A patent/CN101132779B/zh not_active Ceased
- 2006-02-22 DE DE602006017188T patent/DE602006017188D1/de active Active
- 2006-02-22 MX MX2007010856A patent/MX2007010856A/es active IP Right Grant
- 2006-02-22 KR KR1020077020370A patent/KR101335932B1/ko active IP Right Review Request
- 2006-02-22 AT AT06707141T patent/ATE482693T1/de active
- 2006-02-27 GT GT200600096A patent/GT200600096A/es unknown
- 2006-03-03 DO DO2006000057A patent/DOP2006000057A/es unknown
- 2006-03-03 AR AR20060100820A patent/AR054234A1/es not_active Application Discontinuation
- 2006-03-03 MY MYPI20060919A patent/MY162319A/en unknown
- 2006-03-06 UY UY29410A patent/UY29410A1/es not_active Application Discontinuation
- 2006-03-06 TW TW095107345A patent/TWI324928B/zh active
- 2006-03-06 PE PE2006000250A patent/PE20061345A1/es active IP Right Grant
- 2006-03-07 HN HN2006009702A patent/HN2006009702A/es unknown
-
2007
- 2007-08-27 IL IL185517A patent/IL185517A/en active IP Right Grant
- 2007-08-28 CR CR9348A patent/CR9348A/es unknown
- 2007-08-30 CU CU20070203A patent/CU23821A3/es active IP Right Grant
- 2007-09-05 ZA ZA200707638A patent/ZA200707638B/xx unknown
- 2007-09-06 TN TNP2007000341A patent/TNSN07341A1/en unknown
- 2007-10-02 MA MA30267A patent/MA29378B1/fr unknown
- 2007-10-05 NO NO20075042A patent/NO343834B1/no unknown
-
2008
- 2008-08-19 HK HK08109248.3A patent/HK1118019A1/zh unknown
-
2010
- 2010-12-06 HR HR20100674T patent/HRP20100674T1/hr unknown
- 2010-12-10 CY CY20101101138T patent/CY1111065T1/el unknown
-
2015
- 2015-10-22 HK HK15110355.1A patent/HK1209620A1/xx unknown
-
2017
- 2017-08-22 US US15/683,210 patent/US20180036249A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
MA47399B1 (fr) | Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 | |
MA30085B1 (fr) | Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione | |
MA29550B1 (fr) | Derives de n- (pyridine-2-yl) - sulfonamide | |
MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
MA29213B1 (fr) | Quinolones a substitution macrolones - amino | |
MA31496B1 (fr) | Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c | |
MA29692B1 (fr) | Derives de la xanthine en tant qu'agonistes selectifs du hm74a | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
MA29543B1 (fr) | Procedes pour traiter un cancer pharmacoresistant | |
MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
MA27427A1 (fr) | Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA34308B1 (fr) | Triazolopyridines substituées | |
CA2407100A1 (fr) | 1-aroyle-piperidinyle benzamidines | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
ATE449081T1 (de) | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen | |
NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
MA31867B1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
MA28269A1 (fr) | Arylpyrazoles substitués servant d'agents parasiticides | |
MY145074A (en) | Thiazolidin-4-one derivatives | |
TNSN06440A1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer |